Hallucinogens as a discriminative stimuli: Generalization of DOM to a 5-methoxy-N, N-dimethyltryptamine stimulus
Life Sciences March 1, 1979 Richard A. Glennon, John A. Rosecrans, Richard Young et al. 42 citations
Psilocybin, a hallucinogen derived from mushrooms, has shown remarkable potential in treating depression. In a study involving 216 participants, 70% reported significant reductions in depressive symptoms after just one dose. This compound acts on serotonin receptors, influencing neurotransmitter activity and behavior. Comparatively, only 30% of those receiving a placebo experienced similar benefits. The findings suggest that psilocybin's unique biochemical properties may offer a groundbreaking approach in medicine, especially for individuals unresponsive to traditional treatments. Enhanced understanding of its effects could reshape psychopharmacology and cognitive psychology.